« Return to News | Drug Sponsors

Lundbeck, CHDI Foundation collaborate on Huntington’s disease

Tuesday, May 22, 2012 10:23 AM

Lundbeck, a pharmaceutical company based in Deerfield, Ill. and CHDI Foundation, a not-for-profit biomedical research organization, have formed a research collaboration to investigate a targeted therapy for Huntington’s disease.

As part of the collaboration CHDI will conduct pre-clinical studies on a Lundbeck investigative compound. Research will focus on the compound’s effect on P2X receptors that may be involved in Huntington’s. The study results will influence future research into this and other compounds for Huntington’s.

“One of our important functions at CHDI is to seek out promising research ideas in the HD field, and this includes this interesting new work on Lundbeck’s compound,” noted Ignacio Munoz-Sanjuan, vice president of translational biology, CHDI. “Lundbeck has a proven track record of not only bringing new therapies to market but also working to support the needs of their patient communities. We hope this research collaboration provides a stepping stone for future therapies that slow the progression of HD.”

Currently, no treatment exists to slow or halt the progression of Huntington’s disease, a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive and motor symptoms.

Staffan Schüberg, president of Lundbeck, added, “We are also pleased that this announcement coincides with HD Awareness Month, to help draw attention to the need to find therapies for this degenerative neurological disease.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.